Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims

Regeneron Pharmaceuticals Inc. shouldn’t be allowed to split off and delay Eylea antitrust claims alleging it fraudulently obtained patents to preserve a monopoly on the the blockbuster eye-disease drug and hinder competition from its biosimilar Pavblu, Amgen Inc. told a federal judge.

Bifurcating and staying those counterclaims would create duplicative discovery fights over overlapping patent and antitrust issues and delay resolution of Regeneron’s alleged liability, according to Amgen’s brief filed Jan. 9 opposing Regeneron’s motion in the US District Court for the Northern District of West Virginia.

The proposed split also would stay the antitrust claims until after the patent ...